Neurocil (Levomepromazine Maleate)

Levomepromazine maleate, the active ingredient in Neurocil, is a phenothiazine presented as an oral formulation for oral use. It is used to manage schizophrenia, severe agitation, nausea, vomiting, and for palliative sedation in appropriate patients.

GNH USA supplies Neurocil as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine is a phenothiazine antipsychotic that acts on dopamine pathways and is employed in several clinical situations.

Schizophrenia: reduction of psychotic symptoms such as hallucinations and delusions. Severe agitation: calming effect to control extreme restlessness and aggression. Nausea and vomiting: control of refractory nausea when other agents are ineffective. Palliative sedation: provision of deep sedation for end‑of‑life comfort in terminal patients.

Levomepromazine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness. - Orthostatic hypotension leading to dizziness. - Dry mouth and reduced salivation. - Constipation. - Extrapyramidal symptoms such as tremor or rigidity.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome, a life‑threatening reaction. - Torsades de pointes or other serious cardiac arrhythmias. - Severe hypotension or syncope. - Agranulocytosis or severe blood dyscrasias. - Seizures, especially at high doses.

When prescribing Levomepromazine, clinicians should observe several safety measures.

Cardiovascular assessment: monitor blood pressure and heart rate for orthostatic changes. Extrapyramidal monitoring: watch for early signs of movement disorders. Hepatic/renal function: adjust use in patients with impaired metabolism or excretion. Elderly caution: increased sensitivity to sedation and hypotension. Avoid abrupt discontinuation: taper to reduce withdrawal effects. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levomepromazine can interact with a variety of medicines, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., barbiturates, benzodiazepines) may enhance sedation. - Anticholinergic drugs can increase anticholinergic burden. - QT‑prolonging agents (e.g., quinidine, haloperidol) raise risk of arrhythmia. - MAO inhibitors may cause hypertensive crises. - Lithium can increase neurotoxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive agents may potentiate hypotension. - Antidiabetic medications may require dose adjustment due to altered glucose control. - CYP450 inhibitors or inducers can modify levomepromazine plasma levels. - Alcohol consumption can increase central nervous system depression. - Concomitant use with other antipsychotics may heighten extrapyramidal risk.